NASD · Healthcare · Drug Manufacturers - Specialty & Generic · USA
Indivior Pharmaceuticals Inc is a mid cap company (market value between $2 billion and $10 billion) in the Drug Manufacturers - Specialty & Generic industry.
Indivior Pharmaceuticals is a pharmaceutical company that develops and distributes medications for opioid use disorder. The company's core products include SUBLOCADE, a monthly injectable buprenorphine treatment, and SUBOXONE Film, a sublingual medication combining buprenorphine and naloxone. Indivior distributes its products primarily in the U.S., with additional availability in Canada, Australia, France, and Germany.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Indivior Pharmaceuticals Inc stock.
Slightly undervalued: intrinsic value $43.21 per share, market price $34.77, margin of safety 19.5% (as of 2026-10-20).
Discounting its cash flows at 10.2% (average of 3 methods) values the shares at $43.21; the price of $34.77 is 20% below that value, and 72% of that value comes from beyond year five.
17 more funds hold it; the full list is part of the paid plan.
All 84 Drug Manufacturers - Specialty & Generic stocks
6 more in this industry show a wider margin of safety.
INDV is slightly undervalued (as of the 2026-10-20 close). Discounting its cash flows at 10.2% (average of 3 methods) values the shares at $43.21; the price of $34.77 is 20% below that value, and 72% of that value comes from beyond year five.
$43.21 per share (as of the 2026-10-20 close), against a market price of $34.77. That is a margin of safety of 19.5%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.